Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aipalolitovorelizumab (QL1706) + Bevacizumab + Chemotherapy in 1L MSS/pMMR BRAF V600E mCRC
NCT07229846Phase 2Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in colorectal cancer (CRC). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07229846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229846.